GENMAB
Research GENMAB (GE9) on Bullrun: market cap EUR 17.74B, P/E 26.7. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGE9
- ExchangeDU
- CountryDenmark
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 17.74B
- P/E26.7
- Financial periodQ1 2026
- RevenueUSD 896.00M
- Net incomeUSD 53.00M
- Free cash flow-USD 2.00M
- Gross margin92.7%
Valuation Snapshot
latest market cap is EUR 17.74B; P/E is 26.7.
Peer valuation comparison
Latest P/E is 26.66x versus a Healthcare sector median of 24.46x (9.0% above).
Latest P/E is 26.66x versus a Denmark median of 19.06x (39.9% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 3.72B | USD 963.00M | USD 1.15B | 93.6% | 15.37 | USD 1.52B | USD 5.21B | USD 5.68B |
| FY2024 | USD 3.12B | USD 1.13B | USD 1.10B | 95.4% | 17.53 | USD 1.38B | USD 0 | USD 5.14B |
| FY2023 | USD 2.39B | USD 631.00M | USD 1.02B | 98.6% | 9.58 | USD 2.20B | USD 0 | USD 4.69B |
| FY2022 | USD 14.51B | USD 5.45B | USD 3.60B | 100.0% | 82.59 | USD 1.42B | n/a | USD 3.92B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | EUR 17.74B | 26.7 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About GENMAB
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is GENMAB's market cap?
GENMAB's market capitalization is EUR 17.74B.
What is GENMAB's P/E ratio?
GENMAB's price-to-earnings (P/E) ratio is 26.7.
What does GENMAB do?
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.